176 related articles for article (PubMed ID: 8757020)
21. Functional neuroanatomical correlates of the executive clock drawing task (CLOX) performance in Alzheimer's disease: a FDG-PET study.
Shon JM; Lee DY; Seo EH; Sohn BK; Kim JW; Park SY; Kim SG; Jhoo JH; Woo JI
Neuroscience; 2013 Aug; 246():271-80. PubMed ID: 23673275
[TBL] [Abstract][Full Text] [Related]
22. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
[TBL] [Abstract][Full Text] [Related]
23. Concordance between (99m)Tc-ECD SPECT and 18F-FDG PET interpretations in patients with cognitive disorders diagnosed according to NIA-AA criteria.
Ito K; Shimano Y; Imabayashi E; Nakata Y; Omachi Y; Sato N; Arima K; Matsuda H
Int J Geriatr Psychiatry; 2014 Oct; 29(10):1079-86. PubMed ID: 24687634
[TBL] [Abstract][Full Text] [Related]
24. Regional cerebral glucose transport and utilization in Alzheimer's disease.
Friedland RP; Jagust WJ; Huesman RH; Koss E; Knittel B; Mathis CA; Ober BA; Mazoyer BM; Budinger TF
Neurology; 1989 Nov; 39(11):1427-34. PubMed ID: 2812318
[TBL] [Abstract][Full Text] [Related]
25. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
26. Brain FDG PET study of normal aging in Japanese: effect of atrophy correction.
Yanase D; Matsunari I; Yajima K; Chen W; Fujikawa A; Nishimura S; Matsuda H; Yamada M
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):794-805. PubMed ID: 15759148
[TBL] [Abstract][Full Text] [Related]
27. Alzheimer Disease and Mild Cognitive Impairment: Integrated Pulsed Arterial Spin-Labeling MRI and
Riederer I; Bohn KP; Preibisch C; Wiedemann E; Zimmer C; Alexopoulos P; Förster S
Radiology; 2018 Jul; 288(1):198-206. PubMed ID: 29762090
[TBL] [Abstract][Full Text] [Related]
28. Preferential metabolic involvement of visual cortical areas in a subtype of Alzheimer's disease: clinical implications.
Pietrini P; Furey ML; Graff-Radford N; Freo U; Alexander GE; Grady CL; Dani A; Mentis MJ; Schapiro MB
Am J Psychiatry; 1996 Oct; 153(10):1261-8. PubMed ID: 8831432
[TBL] [Abstract][Full Text] [Related]
29. [Relationship between three neuropsychological tests and cerebral glucose metabolism in Alzheimer's disease].
Zhang XQ; Min BQ; Ma YC; Yang PJ; Li DP
Zhonghua Yi Xue Za Zhi; 2003 Jan; 83(2):100-2. PubMed ID: 12812674
[TBL] [Abstract][Full Text] [Related]
30. Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators.
Alavi A; Newberg AB; Souder E; Berlin JA
J Nucl Med; 1993 Oct; 34(10):1681-7. PubMed ID: 8410281
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous resting-state FDG-PET/fMRI in Alzheimer Disease: Relationship between glucose metabolism and intrinsic activity.
Marchitelli R; Aiello M; Cachia A; Quarantelli M; Cavaliere C; Postiglione A; Tedeschi G; Montella P; Milan G; Salvatore M; Salvatore E; Baron JC; Pappatà S
Neuroimage; 2018 Aug; 176():246-258. PubMed ID: 29709628
[TBL] [Abstract][Full Text] [Related]
32. Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer's disease.
Samuraki M; Matsunari I; Chen WP; Yajima K; Yanase D; Fujikawa A; Takeda N; Nishimura S; Matsuda H; Yamada M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1658-69. PubMed ID: 17520250
[TBL] [Abstract][Full Text] [Related]
33. Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains.
Ishii K; Willoch F; Minoshima S; Drzezga A; Ficaro EP; Cross DJ; Kuhl DE; Schwaiger M
J Nucl Med; 2001 Apr; 42(4):548-57. PubMed ID: 11337540
[TBL] [Abstract][Full Text] [Related]
34. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
[TBL] [Abstract][Full Text] [Related]
35. Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia.
Mielke R; Heiss WD
J Neural Transm Suppl; 1998; 53():237-50. PubMed ID: 9700661
[TBL] [Abstract][Full Text] [Related]
36. Reductions in parietal and temporal cerebral metabolic rates for glucose are not specific for Alzheimer's disease.
Schapiro MB; Pietrini P; Grady CL; Ball MJ; DeCarli C; Kumar A; Kaye JA; Haxby JV
J Neurol Neurosurg Psychiatry; 1993 Aug; 56(8):859-64. PubMed ID: 8350100
[TBL] [Abstract][Full Text] [Related]
37. Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer's disease dementia.
Castellano CA; Nugent S; Paquet N; Tremblay S; Bocti C; Lacombe G; Imbeault H; Turcotte É; Fulop T; Cunnane SC
J Alzheimers Dis; 2015; 43(4):1343-53. PubMed ID: 25147107
[TBL] [Abstract][Full Text] [Related]
38. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.
Mosconi L
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):486-510. PubMed ID: 15747152
[TBL] [Abstract][Full Text] [Related]
39. The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization.
Desgranges B; Baron JC; de la Sayette V; Petit-Taboué MC; Benali K; Landeau B; Lechevalier B; Eustache F
Brain; 1998 Apr; 121 ( Pt 4)():611-31. PubMed ID: 9577389
[TBL] [Abstract][Full Text] [Related]
40. Bihemispheric cerebral FDG PET correlates of cognitive dysfunction as assessed by the CERAD in Alzheimer's disease.
Schönknecht OD; Hunt A; Toro P; Guenther T; Henze M; Haberkorn U; Schröder J
Clin EEG Neurosci; 2011 Apr; 42(2):71-6. PubMed ID: 21675596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
